A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

Status:
Completed

Trial end date:
2019-06-28

Target enrollment:

Participant gender:

A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod

Phase 4

Novartis Pharmaceuticals

Fingolimod Hydrochloride